Ranked #1
Accelerated-phase MPNs: mutational landscape, challenges, and novel treatment strategies being explored
Accelerated-phase MPNs: mutational landscape, challenges, and novel treatment strategies being explored
Patients with BCR-ABL negative myeloproliferative neoplasms (MPNs) are at risk of progressing to accelerated-phase or bl... Read more
10 Aug 2023
•
8mins
Ranked #2
Determining the optimal sequencing of bispecifics and CAR-T cells in multiple myeloma
Determining the optimal sequencing of bispecifics and CAR-T cells in multiple myeloma
Bispecific antibodies and CAR-T cells have transformed the myeloma treatment landscape in recent years, providing hope f... Read more
3 Aug 2023
•
7mins
Similar Podcasts
Ranked #3
Overcoming barriers to CAR-T therapy: improving access and cost
Overcoming barriers to CAR-T therapy: improving access and cost
CAR-T therapy has become a promising novel option for patients with relapsed/refractory (R/R) hematological malignancies... Read more
27 Jul 2023
•
11mins
Ranked #4
The importance of addressing quality of life and improving symptom management in MPNs
The importance of addressing quality of life and improving symptom management in MPNs
Myeloproliferative neoplasms (MPNs) represent a challenging group of diseases to treat, and patients with MPNs suffer fr... Read more
19 Jul 2023
•
6mins
Ranked #5
Updates in the treatment and management of amyloidosis and the importance of the multidisciplinary team
Updates in the treatment and management of amyloidosis and the importance of the multidisciplinary team
Amyloidosis is a rare disease in which insoluble amyloid proteins are deposited in tissues or organs, resulting in organ... Read more
11 Jul 2023
•
8mins
Ranked #6
Hemophilia: the current standard of care and the value of novel gene therapies
Hemophilia: the current standard of care and the value of novel gene therapies
Over the years, the hemophilia treatment landscape has transformed, with novel agents aiming to improve patient care and... Read more
5 Jul 2023
•
6mins
Ranked #7
CLL highlights at EHA 2023: latest advances with the use of BTK inhibitors
CLL highlights at EHA 2023: latest advances with the use of BTK inhibitors
Bruton’s tyrosine kinase (BTK) inhibitors have transformed the treatment landscape of chronic lymphocytic leukemia (CLL)... Read more
29 Jun 2023
•
14mins
Ranked #8
Myeloma highlights at EHA 2023: CARTITUDE-4 & CARTITUDE-1 updates & the use of MRD in clinical practice
Myeloma highlights at EHA 2023: CARTITUDE-4 & CARTITUDE-1 updates & the use of MRD in clinical practice
In recent years, CAR-T cell therapy has transformed the myeloma treatment landscape and has provided a valuable option t... Read more
22 Jun 2023
•
8mins
Ranked #9
Lymphoma highlights at EHA 2023: sequencing bispecifics & CAR-T cells, bridging therapy & toxicity management
Lymphoma highlights at EHA 2023: sequencing bispecifics & CAR-T cells, bridging therapy & toxicity management
The treatment landscape of large B-cell lymphoma (LBCL) has transformed in recent years, with novel immunotherapies incl... Read more
16 Jun 2023
•
16mins
Ranked #10
iwCAR-T Session IV: CAR-T therapy in CLL: challenges, combination approaches and ongoing trials
iwCAR-T Session IV: CAR-T therapy in CLL: challenges, combination approaches and ongoing trials
The 5th International Workshop on CAR-T (iwCAR-T) took place in Scottsdale, AZ, on 14 – 16 April, 2023, and brought toge... Read more
7 Jun 2023
•
12mins